- Home
- MPA vs CHRS Comparison
MPA vs CHRS Comparison
Compare MPA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPA
- CHRS
- Stock Information
- Founded
- MPA 1992
- CHRS 2010
- Country
- MPA United States
- CHRS United States
- Employees
- MPA N/A
- CHRS N/A
- Industry
- MPA Finance Companies
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MPA Finance
- CHRS Health Care
- Exchange
- MPA Nasdaq
- CHRS Nasdaq
- Market Cap
- MPA 159.3M
- CHRS 185.5M
- IPO Year
- MPA N/A
- CHRS 2014
- Fundamental
- Price
- MPA $11.86
- CHRS $1.71
- Analyst Decision
- MPA
- CHRS Strong Buy
- Analyst Count
- MPA 0
- CHRS 4
- Target Price
- MPA N/A
- CHRS $5.38
- AVG Volume (30 Days)
- MPA 25.2K
- CHRS 10.3M
- Earning Date
- MPA 01-01-0001
- CHRS 11-06-2024
- Dividend Yield
- MPA 3.83%
- CHRS N/A
- EPS Growth
- MPA N/A
- CHRS N/A
- EPS
- MPA N/A
- CHRS N/A
- Revenue
- MPA N/A
- CHRS $304,340,000.00
- Revenue This Year
- MPA N/A
- CHRS $1.64
- Revenue Next Year
- MPA N/A
- CHRS $16.98
- P/E Ratio
- MPA N/A
- CHRS N/A
- Revenue Growth
- MPA N/A
- CHRS 44.19
- 52 Week Low
- MPA $9.87
- CHRS $0.66
- 52 Week High
- MPA $12.21
- CHRS $3.70
- Technical
- Relative Strength Index (RSI)
- MPA 34.26
- CHRS 66.61
- Support Level
- MPA $12.25
- CHRS $1.45
- Resistance Level
- MPA $12.55
- CHRS $1.85
- Average True Range (ATR)
- MPA 0.16
- CHRS 0.22
- MACD
- MPA -0.04
- CHRS 0.01
- Stochastic Oscillator
- MPA 9.91
- CHRS 40.98
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with current income exempt from U.S. federal and Pennsylvania income taxes.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.